M
Martin Eatock
Researcher at Belfast City Hospital
Publications - 37
Citations - 1103
Martin Eatock is an academic researcher from Belfast City Hospital. The author has contributed to research in topics: Capecitabine & Cancer. The author has an hindex of 14, co-authored 36 publications receiving 1003 citations. Previous affiliations of Martin Eatock include Belfast Health and Social Care Trust & Queen's University Belfast.
Papers
More filters
Journal ArticleDOI
A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours
Ruth Plummer,Richard H. Wilson,H. Calvert,Alan V. Boddy,MJ Griffin,Julieann Sludden,Michael J. Tilby,Martin Eatock,D.G. Pearson,Chris J. Ottley,Yasuhiro Matsumura,Kazunori Kataoka,T. Nishiya +12 more
TL;DR: The delayed and sustained release of cisplatin after i.v. administration contributes to the low toxicity of NC-6004 and the recommended dose was 90 mg m−2, although DLT was not defined as per protocol.
Journal ArticleDOI
A Phase I study of the Heat Shock Protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced, solid tumors.
Simon Pacey,Richard H. Wilson,Michael I. Walton,Martin Eatock,Anthea Hardcastle,Anna Zetterlund,Hendrik-Tobias Arkenau,Javier Moreno-Farre,Udai Banerji,Belle Roels,Heidi Peachey,Wynne Aherne,Johann S. de Bono,Florence I. Raynaud,Paul Workman,Ian Judson +15 more
TL;DR: The maximum tolerated dose (MTD) was the highest dose at which ≤1/6 patients experienced dose limiting toxicity (DLT) and the recommended phase II dose of 17-DMAG is 80 mg/m2 weekly i.v.
Journal ArticleDOI
The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer
Nicola E. Annels,Victoria Shaw,Rachel F. Gabitass,Lucinda Billingham,Pippa Corrie,Martin Eatock,Juan W. Valle,David B Smith,Jonathan Wadsley,David Cunningham,Hardev Pandha,John P. Neoptolemos,Gary Middleton +12 more
TL;DR: There was no evidence that the addition of low-dose adjuvant GM-CSF increased Lin-DR-CD11b+ MDSC in patients receiving combination chemoimmunotherapy in patients with advanced pancreatic cancer receiving the combination of gem citabine and capecitabine.
Journal ArticleDOI
A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma
Robert Jones,Robert E. Hawkins,Martin Eatock,David Ferry,Ferry A.L.M. Eskens,Hansjochen Wilke,T.R. Jeffry Evans +6 more
TL;DR: DHA-paclitaxel has modest activity in patients with oesophago-gastric cancer and with haematological toxicity that is comparable to pac litaxel and docetaxel.
Journal ArticleDOI
Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer
Martin Eatock,Niall C. Tebbutt,C. L. Bampton,Andrew Strickland,M. Valladares-Ayerbes,Anna Swieboda-Sadlej,E. Van Cutsem,N. Nanayakkara,Yu Nien Sun,Z. D. Zhong,M. B. Bass,Adeboye H. Adewoye,G. Bodoky +12 more
TL;DR: PFS and ORR were estimated to be similar with AMG 386plus CX and placebo plus CX treatment and compared with placebo, toxicity of AMg 386 plus C X was greater but manageable.